OCALA, Fla., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the Q1 Virtual Investor Summit.
| Event | Q1 Investor Summit |
| Date | March 23-25th, 2021 |
| Presentation | March 24th @ 3:00 PM ET |
| Location | https://zoom.us/webinar/register/WN_y7LDL2ROTQqvz3iOVkINMw |
About The Investor Summit
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.
To request complimentary investor registration: please visit the following website at www.investorsummitgroup.com
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of
therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Investor Relations Contact:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com
AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com
Investor Summit Contact:
Brittney Blocker at brittney@investorsummitgroup.com
Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com